Comparative Pharmacology
Head-to-head clinical analysis: METRONIDAZOLE HYDROCHLORIDE versus VANDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRONIDAZOLE HYDROCHLORIDE versus VANDAZOLE.
METRONIDAZOLE HYDROCHLORIDE vs VANDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.
VANDAZOLE is a nitroimidazole antimicrobial agent that undergoes reduction by bacterial nitroreductases, forming cytotoxic free radicals that damage DNA and inhibit nucleic acid synthesis.
Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.
2 g orally as a single dose once daily for 2 days.
None Documented
None Documented
7-8 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment.
Approximately 8-10 hours in adults; prolonged to 20-25 hours in hepatic impairment.
Renal 60-80% as unchanged drug and metabolites; fecal 6-15%; biliary minor.
Primarily renal (40-70% unchanged), with biliary/fecal elimination accounting for 15-20% as metabolites.
Category A/B
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic